HDAC6 and ovarian carcinoma: Histone deacetylase 6 (HDAC6), which has the potential to be a predictive biomarker for melanoma and ovarian cancer[18, 19], also regulates epigenetic resistance to PD-1 immunotherapy in melanoma patients.